Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Hugel Inc (145020 KS): Favorable Court Ruling Paves US Entry; Record High 1Q Sales

Hugel Inc (145020 KS): Achieves Record High Revenue and Operating Profit in 4Q23

Hugel Inc (145020 KS): Achieves Record High Revenue in 2Q23; Resubmits Marketing Application in US

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hugel-inc" target="_blank" data-smartkarma-citation="entities:22860:1" rel="noopener">Hugel Inc (145020 KS)</a> achieved revenue and operating profit of KRW105B and KRW53B in 3Q24, up 24% and 55%, YoY, respectively. Both botulinum toxin and fillers performed strongly.</li>
<li>Botulinum toxin's overseas sales jumped 73% YoY during the quarter, thanks to the initial shipment to the U.S. in July and September and robust growth from the Asia-Pacific market.</li>
<li>After the favorable ruling of ITC, Hugel plans to officially launch Botulax later this year in the U.S. market via collaborations with its California-based partner Benev Company.</li>
</ul>



Hugel Inc (145020 KS) achieved revenue and operating profit of KRW105B and KRW53B in 3Q24, up 24% and 55%, YoY, respectively. Both botulinum toxin and fillers performed strongly.
Botulinum toxin's overseas sales jumped 73% YoY during the quarter, thanks to the initial shipment to the U.S. in July and September and robust growth from the Asia-Pacific market.
After the favorable ruling of ITC, Hugel plans to officially launch Botulax later this year in the U.S. market via collaborations with its California-based partner Benev Company.


Hugel Inc (145020 KS): Record High Quarterly Sales and Operating Profit in 3Q; US Launch to Start